Jeffrey Scott Sherman
Jeffrey Scott Sherman's purchase track record
Jeffrey Scott Sherman has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/6/2025 | NEO | $112K | +90.0% | +118.0% | +8.5% |
| 5/2/2025 | NEO | $150K | -33.0% | +26.9% | +20.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Privia Health to Report Q3 2026 Results on Nov 5. Privia Health Group is scheduled to announce its third-quarter 2026 financial results on November 5. Recent coverage highlights the company's role in healthcare automation aimed at reducing administrative costs. With the stock currently trading near its support level, investors will be watching the earnings report for updates on revenue trends and cost management.
Transaction History
| NEO | ▲ Buy | Option Exercise | 15,535 | $0 | 2/23/2026 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 3,783 | $0 | 2/23/2026 | View on chart |
| NEO | ▲ Buy | Option Exercise | 42,158 | $0 | 2/21/2026 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 10,729 | $0 | 2/21/2026 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 11,938 | $0 | 12/7/2025 | View on chart |
| NEO | ▲ Buy | Open Market | 20,000 | $112K | 8/6/2025 | View on chart |
| NEO | ▲ Buy | Option Exercise | 13,005 | $0 | 5/11/2025 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 3,167 | $0 | 5/11/2025 | View on chart |
| NEO | ▲ Buy | Open Market | 20,000 | $150K | 5/2/2025 | View on chart |
| NEO | ▲ Buy | Option Exercise | 15,535 | $0 | 2/23/2025 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 4,207 | $0 | 2/23/2025 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 11,746 | $0 | 12/7/2024 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 3,167 | $47K | 5/11/2024 | View on chart |
| NEO | ▲ Buy | Option Exercise | 13,005 | $0 | 5/11/2024 | View on chart |
| NEO | ▲ Buy | Option Exercise | 13,005 | $0 | 5/11/2024 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 8,147 | $0 | 12/7/2023 | View on chart |
| NEO | ▲ Buy | Grant | 89,206 | $0 | 12/5/2022 | View on chart |
| NEO | ▲ Buy | Grant | 44,603 | $0 | 12/5/2022 | View on chart |
| PRVA | ▲ Buy | Grant | 61,307 | $0 | 1/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.